Dermata Therapeutics (DRMA) Competitors $3.97 -0.02 (-0.50%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.12 +0.15 (+3.88%) As of 10/17/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. SLXN, GELS, KALA, APM, INAB, LSB, CARM, HOOK, AEON, and SNPXShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Silexion Therapeutics (SLXN), Gelteq (GELS), KALA BIO (KALA), Aptorum Group (APM), IN8bio (INAB), LakeShore Biopharma (LSB), Carisma Therapeutics (CARM), HOOKIPA Pharma (HOOK), AEON Biopharma (AEON), and Synaptogenix (SNPX). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors Silexion Therapeutics Gelteq KALA BIO Aptorum Group IN8bio LakeShore Biopharma Carisma Therapeutics HOOKIPA Pharma AEON Biopharma Synaptogenix Silexion Therapeutics (NASDAQ:SLXN) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability. Does the media favor SLXN or DRMA? In the previous week, Dermata Therapeutics had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 2 mentions for Dermata Therapeutics and 1 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 1.00 beat Dermata Therapeutics' score of -1.00 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silexion Therapeutics Positive Dermata Therapeutics Negative Do institutionals and insiders hold more shares of SLXN or DRMA? 10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 6.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 18.5% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate SLXN or DRMA? Silexion Therapeutics presently has a consensus price target of $75.00, suggesting a potential upside of 2,030.68%. Dermata Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 151.89%. Given Silexion Therapeutics' higher possible upside, analysts plainly believe Silexion Therapeutics is more favorable than Dermata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is SLXN or DRMA more profitable? Silexion Therapeutics' return on equity of 0.00% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -355.74% Dermata Therapeutics N/A -214.98%-153.76% Which has higher valuation & earnings, SLXN or DRMA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A-$16.44MN/AN/ADermata TherapeuticsN/AN/A-$12.29M-$16.41-0.24 Which has more volatility & risk, SLXN or DRMA? Silexion Therapeutics has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. SummaryDermata Therapeutics beats Silexion Therapeutics on 5 of the 9 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.72M$3.39B$6.09B$10.49BDividend YieldN/A2.28%5.73%4.81%P/E Ratio-0.2422.4484.5227.09Price / SalesN/A429.44568.62202.80Price / CashN/A46.5937.1661.22Price / Book0.6410.4112.246.52Net Income-$12.29M-$52.47M$3.32B$276.75M7 Day Performance-4.34%2.32%1.25%1.97%1 Month Performance-30.72%11.14%6.28%2.23%1 Year Performance-75.34%11.15%59.92%35.58% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics1.4612 of 5 stars$3.97-0.5%$10.00+151.9%-74.9%$2.72MN/A-0.248News CoverageNegative NewsShort Interest ↑SLXNSilexion Therapeutics3.2331 of 5 stars$3.86-0.3%$75.00+1,843.0%-92.5%$12.08MN/A0.00N/APositive NewsShort Interest ↓GELSGelteqN/A$1.24-0.8%N/AN/A$11.70MN/A0.00N/AShort Interest ↓KALAKALA BIO4.0051 of 5 stars$1.64+7.9%$20.38+1,142.4%-74.4%$11.51MN/A-0.2430Short Interest ↑High Trading VolumeAPMAptorum Group1.2721 of 5 stars$2.09-9.9%N/A-6.6%$11.18MN/A0.0030Short Interest ↓Gap DownINABIN8bio3.6045 of 5 stars$2.46+4.7%$180.00+7,217.1%-70.0%$11.17MN/A-0.2720Positive NewsAnalyst UpgradeGap DownLSBLakeShore BiopharmaN/A$0.53-33.0%N/A-84.2%$11.01M$85.67M0.00773High Trading VolumeCARMCarisma Therapeutics2.5396 of 5 stars$0.26+2.5%$1.93+633.6%-96.3%$10.97M$19.63M-0.1720News CoverageGap UpHOOKHOOKIPA Pharma2.8919 of 5 stars$0.90-0.4%$4.50+401.7%-79.1%$10.93M$9.35M-0.15160AEONAEON Biopharma0.5336 of 5 stars$0.94+10.0%N/A-98.6%$10.89MN/A5.205Gap DownSNPXSynaptogenixN/A$7.71+20.3%N/A+148.9%$10.72MN/A-0.764 Related Companies and Tools Related Companies SLXN Competitors GELS Competitors KALA Competitors APM Competitors INAB Competitors LSB Competitors CARM Competitors HOOK Competitors AEON Competitors SNPX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRMA Stock Alerts